Cisplatin, a chemotherapeutic used for the treatment of solid cancers, has nephrotoxic side 26 effects leading to acute kidney injury (AKI). Cisplatin cannot be given to patients that have 27 comorbidities that pre-dispose them to an increased risk for AKI. Even without these 28 comorbidities, 30% of patients administered cisplatin will develop kidney injury, requiring the 29 oncologist to withhold or reduce the next dose, leading to a less effective therapeutic regimen. 
Introduction 45
Acute kidney injury (AKI), the rapid loss of kidney function, has many medical 46 complications, a high mortality rate, and limited therapeutic interventions beyond palliative care 47
Total RNA was isolated using RNA-STAT 60 (TEL-TEST Inc., Friendswood, TX) combined with 145 mini-bead-beater glass beads and Mini Bead Beater machine (Cole-Palmer, Vernon Hills, IL) 146 following manufacturer's protocol. cDNA was made from 1 µg of total RNA using High Capacity 147
Reverse Transcriptase (Life Technologies, Grand Island NY) following manufacturers' 148 instructions. Gene specific cDNAs were quantitated using real-time PCR and predesigned 149 TaqMan assays. Tumor necrosis factor-alpha (TNF-α) (Mm00443258_m1), interleukin 6 (IL6) 150 (Mm00446190_m1), interleukin 1-β (IL1β) (Mm0043228_m1), C-X-C motif ligand 1 (CXCL1) 151 (Mm04207460_m1), monocyte chemotactic protein 1 (MCP1) (Mm00441242_m1), plasminogen 152 activator inhibitor-1 (PAI-1) (Mm00435860_m1), α-smooth muscle actin (α-SMA) 153 (Mm1546133_m1), bone morphogenetic protein-7 (BMP-7) (Mm00432102_m1), collagen α 154 1(IV) chain (COL4α1) (Mm01210125_m1), cyclin-dependent kinase inhibitor 2A (CDK2NA) 155 (Mm00491449-m1), connective tissue growth factor (CTGF) (Mm01192932_g1), α-1 type 1 156 collagen (COL1α1) (Mm00801666_g1), and the normalization genes (β-2 microglubilin (B2M) 157 (Mm00437762_m1) and β-actin (Mm01205647-g1) were purchased from Life Technologies 158 (Grand Island NY) and used in combination with 2X Gene expression Master Mix (Life 159 Technologies). 160
Histology 161
Kidney sections (5μm thick) from cisplatin-treated and untreated animals were stained with H&E 162 and PAS, and the degree of morphologic changes was determined by light microscopy in a 163 blinded fashion by a renal pathologist. The following measures were chosen as an indication of 164 morphologic damage to the kidney after treatment with vehicle or cisplatin: proximal tubular 165 necrosis, loss of brush border, proximal tubule degradation, tubular casts, presence of 166 inflammatory cells, and interstitial fibrosis These measures were evaluated on a scale from 0 167 to 4, which ranged from not present (0), mild (1), moderate (2), severe (3), and very severe (4). 168
Immunohistochemistry
Kidney sections (5 μm thick) were rehydrated in Histoclear followed by an ethanol gradient. 170
Antigen retrieval was performed in citric acid buffer pH 6.0 at 95°C in a steamer for 30 min. 171
Endogenous peroxidases were inhibited with 3% hydrogen peroxide and dual endogenous 172 enzyme blocker (Dako) for 10 min, followed by two 5-min PBS washes. Slides were then 173 blocked with avidin for 10 minutes followed by a PBS wash, and then biotin for 10 minutes 174 followed by a wash in PBS (Dako). Slides were further blocked with 5% normal goat serum in 175 0.1% TBST for 1 h at room temperature. α-SMA primary rabbit antibody (Abcam) was added to 176 slides at a concentration of 0.5 µg/mL, and allowed to incubate at 4°C overnight. Biotinylated 177 goat anti-rabbit IgG antibody (1: 25000) (Vector laboratories, BA-1000) was added to each 178 section and incubated for 30 min at room temperature. Slides were rinsed twice with PBS (5 179 minutes each). Vector ABC reagent (Vector laboratories, PK-7100) was added to each section 180 and incubated for 30 min at room temperature. Slides were rinsed 2X with PBS, followed by the 181 addition HRP was detected with NovaRed Substrate (Vector Laboratories, SK-4800) to each 182 section for 5-7 min. Slides were rinsed in distilled water for 5 minutes, counterstained with 183 modified Mayer's hematoxylin (thermo scientific, 72804), then dehydrated in an ethanol gradient 184 to Histoclear, followed by mounting with Permount (Fisher Scientific, SP15). Positive staining 185 for α-SMA was quantified using Metamorph Image Analysis software, and percent positive 186 pixels were calculated as follows: (threshold area/(total area-acellular area)). 187
Sirius Red/ Fast Green Staining 188
Kidney sections (5 μm thick) were rehydrated in Histoclear followed by an ethanol gradient. 189
Slides were then dipped into a Coplin jar containing 
Results

208
Effects of dosing regimens on mouse survival. The current model used to study cisplatin-209 induced AKI does not allow for the analysis of long-term effects on kidney function, nor does it 210 recapitulate the repeated nature of the dosing regimen of cisplatin in the clinic. We hypothesized 211 that administration of a low dose of cisplatin once a week for several weeks would be more 212 clinically relevant and allow for analysis of long-term effects on kidney function. To test this, we 213 compared survival of mice given a single high dose of cisplatin (standard dosing model; 25 214 mg/kg) to mice given a dose of cisplatin (7 or 9 mg/kg) once a week for 4 weeks. All mice 215 subjected to the standard dosing regimen were sacrificed three days after cisplatin injection due 216 to moribund status. Mice treated with the 7 mg/kg repeated dosing regimen survived the course 217 of treatment and were sacrificed 3 days after the fourth treatment (day 24). Ninety percent of 218 mice treated with a 9 mg/kg repeated dosing regimen survived until day 24 (Fig1). Statistical 219 analyses comparing survival curves of 7 and 9 mg/kg treated mice revealed no statistical 220 significance, but there was statistical significance between repeated dosing and standard dosing 221 survival curves (Fig1). These data indicate that the repeated dosing model with 7 mg/kg 222 enables survival of all treated mice for long-term studies of kidney function. 223
224
Effects of dosing regimens on kidney injury and function. In order to assess the impact of 225 repeated dosing on the kidney, we measured markers of kidney function and injury in the serum 226 and urine of mice, respectively. BUN levels of mice treated with the standard dosing model were 227 significantly increased at 72 h post-treatment (Fig2A). In the repeated dosing model, BUN also 228 increased, but not significantly (Fig2A). SCr levels were significantly increased for both the 229 repeated and standard dosing models, but SCr levels were higher in the standard dosing model 230 (Fig2A). Urinary KIM-1 and NGAL levels were examined, as they are more sensitive biomarkers 231 of AKI than BUN and SCr (5, 6). Urinary KIM-1 and NGAL levels were significantly increased in 232 the standard dosing model, but only NGAL levels were significantly increased in the repeated 233 dosing model, albeit to a lesser extent than in the standard model ( Fig 2B) . These data indicate 234 that the repeated dosing model of cisplatin induced less kidney injury and less decreased 235 kidney function, as compared to the standard dosing model. in the standard dosing model (22, 25, 39) . Therefore, we assessed cellular markers of ER 253 stress and cell death proteins in both models. JNK phosphorylation and activation is associated 254 with ER stress-induced apoptosis (37, 49). We found that pJNK was elevated in both models 255 (Fig4). CHOP is also associated with ER stress, and was also activated in both models (Fig4) 
model. 297
Comparison of a single, low dose of cisplatin (7VVV) to repeated dosing model. To 299
determine if fibrosis is a result of a single, low dose of cisplatin, or rather repeated injury from 300 several low doses, mice were administered a low dose of cisplatin (7 mg/kg) followed by three 301 weekly vehicle injections (7VVV) and compared to mice receiving 4 weekly cisplatin injections 302 Treatment of human cancers with cisplatin often leads to nephrotoxic side effects that 315 are cumulative and dose dependent. AKI occurs in some individuals even after one low dose of 316 cisplatin, and multiple episodes of AKI can cause chronic kidney disease (CKD) (13). While 317
Kobayashi et al. performed repeated cisplatin dosing in mice to determine circadian changes 318 related to drug administration, here we have developed a model to study the effects of multiple 319 "hits" of cisplatin-induced AKI and the subsequent development of CKD (31). The standard 320 dosing model of cisplatin-induced AKI has limitations that cannot be overcome for studying AKI 321 to CKD progression. For one, a single, high dose regimen is not clinically relevant. Patients are 322 administered multiple low doses of cisplatin over an extended period of time. Secondly, thestandard dosing model cannot be aged out to study long-term effects associated with repeated 324 AKI, namely fibrosis-the underlying pathology of CKD (7). Here, we report a model for 325 studying the nephrotoxic effects of cisplatin that mimics the repeated administration of cisplatin 326 given clinically and allows for analysis of long-term effects on kidney function. Data obtained 327 from this model indicate that repeated cisplatin injury induces interstitial fibrosis and suggest 328 that targeting fibrotic mediators may prevent both short-and long-term renal side effects of 329
cisplatin. 330
The standard dosing model of cisplatin induces high levels of kidney injury and cell 331 death through apoptosis and necrosis. This in turn results in a rapid loss of kidney function. 332
With the repeated dosing model, cleaved caspase 3 as a measure of apoptosis is low, and 333 pathology reveals a low level of tubular necrosis. This translates to lower injury levels and a 334 smaller decline in overall kidney function. These lower levels of injury and the maintenance of 335 kidney function with the repeated dosing model may be key to explaining how mice treated with 336 multiple low doses of cisplatin are able to survive for 24 days, and perhaps even beyond that. 337
In the standard dosing model of cisplatin-induced AKI there is a strong inflammatory 338 response, which involves TNFα elevation and elevation of its downstream targets. In the 339 repeated dosing model, a similar inflammatory response is observed. However, IL6 expression 340 is not as elevated in the repeated dosing model. IL6 plays a role in mounting an effective 341 immune response and has been indicated in AKI. Particularly, IL6 expression is correlated with 342 the onset and severity of AKI, and has been indicated as a potential urinary and plasma 343 biomarker of AKI (19, 36, 50) . The low levels of IL6 mRNA measured in the repeated dosing 344 model may be indicative of a less severe form of AKI, and help explain why less injury is 345 occurring in this model. repeated injury in this model culminated in fibrosis as determined by increased levels of TGFβ-360 1, fibronectin, and collagen1α1 (26). . In our model of repeated cisplatin dosing, we also see 361 increased protein levels of TGFβ, fibronectin, and increased mRNA expression of Col1α1. 362 G2/M arrest, cellular senescence, and fibrosis have been indicated in the ischemia-363 reperfusion and unilateral ureteral obstruction mouse models (49). We found increased mRNA 364 expression of Cdk2na, which is suggestive of cellular senescence. Furthermore, pJNK has 365 been indicated as a downstream target of G2/M cell cycle arrest, and is believed to also play a 366 role in promoting renal fibrosis (49). While, further studies are needed to determine whether or 367 not G2/M arrest is indeed occurring following repeated cisplatin dosing, we do observe, an 368 increase in pJNK without evidence of apoptosis.. Thus, the increase in pJNK may be indicative 369 of G2/M arrest occurring, and as a result, potentially maladaptive repair. Taken together, these 370 data suggest that potential mechanisms such as senescence and G2/M arrest warrant future in-371 depth investigation in this model in order to identify the mechanisms by which fibrosis is 372 induced.
Fibrosis plays a major role in our repeated dosing model and is indicative that this modelwith special reference to the kinetics of macrophages and myofibroblasts. Toxicologic pathology 24: 528 199-206, 1996 once (standard dosing model). Mice were monitored daily for weight loss and changes in overall 541
well-being and were sacrificed when moribund in accordance to IACUC guidelines. At day 24, 542 surviving mice were sacrificed and analyzed. 543 performed in a blinded manner by renal pathologist Dr. Megyesi using a scale of 0-4 (0=not 572 present, 1=mild, 2=moderate, 3=severe, and 4=very severe renal histological changes in the 573 proximal tubules). n = 5-10; data are the mean ± SEM. Statistical significance determined by 574 one-way ANOVA followed by Tukey's multiple comparison test, ***indicates p<0.001. 575 -β
